Highlights of weekly biotech stock moves
Regulatory, clinical and other milestones
Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) gained $0.07 to $1.25 on Friday after FDA accepted for review an NDA resubmission for Adasuve (Staccato loxapine) to treat agitation in patients with schizophrenia or bipolar disorder. The PDUFA date is Feb. 4, 2012. Alexza was up $0.03 last week
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) lost $0.95 (10%) to $8.32 last week after EMA accepted for review an MAA from partner Merck & Co. Inc. (NYSE:MRK) for ridaforolimus to treat metastatic sarcomas. The acceptance triggers a $25 million milestone payment to Ariad, from which Merck has exclusive worldwide rights.
Gentium S.p.A. (NASDAQ:GENT) fell $1.94 (22%) to $6.85 on Thursday after withdrawing an NDA for defibrotide because FDA identified numerous issues with the completeness of the dataset for